Evidence map›Paper›PMID 35644262›Full record

ArticleJournal of virological methods2022

Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern.

Kanti Pabbaraju, Nathan Zelyas, Anita Wong, Matthew A Croxen, Tarah Lynch, Emily Buss, Stephanie Murphy, Sandy Shokoples, Jamil Kanji, Graham Tipples

Open access · greenAbstract read
In one paragraph

Article in Journal of virological methods, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Description of COVID-19 outbreaks in childcare facilities in Alberta, March 2020 to December 31, 2021.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2023
    Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Kanti PabbarajuAlberta Precision Laboratories, Public Health Laboratory, Calgary, Alberta, Canada. Electronic address: Kanti.pabbaraju@albertaprecisionlabs.ca.
Nathan ZelyasDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada; Alberta Precision Laboratories, Public Health Laboratory, Edmonton, Alberta, Canada.
Anita WongAlberta Precision Laboratories, Public Health Laboratory, Calgary, Alberta, Canada.
Matthew A CroxenDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada; Alberta Precision Laboratories, Public Health Laboratory, Edmonton, Alberta, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.
Tarah LynchAlberta Precision Laboratories, Public Health Laboratory, Calgary, Alberta, Canada; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada.
Emily BussAlberta Precision Laboratories, Public Health Laboratory, Edmonton, Alberta, Canada.
Stephanie MurphyAlberta Precision Laboratories, Public Health Laboratory, Edmonton, Alberta, Canada; National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Sandy ShokoplesAlberta Precision Laboratories, Public Health Laboratory, Edmonton, Alberta, Canada.
Jamil KanjiAlberta Precision Laboratories, Public Health Laboratory, Calgary, Alberta, Canada; Division of Infectious Diseases, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Graham TipplesAlberta Precision Laboratories, Public Health Laboratory, Edmonton, Alberta, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada; Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.
University of Alberta · CAUniversity of Calgary · CAProvincial Laboratory of Public Health · CAPublic Health Agency of Canada · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In order to detect the SARS-CoV-2 variants of concern (VOCs), five real-time reverse transcriptase PCR (rRT-PCR) assays were designed to target the critical discriminatory mutations responsible for the following amino acid changes in the spike protein: two Δ69-70 + N501Y + E gene triplexes (one optimized for Alpha [B.1.1.7] and one optimized for Omicron [B.1.1.529]), a K417N + 242-244 wild-type duplex, a K417T + E484K duplex, and a L452R + P681 + E484Q triplex. Depending on the assay, sensitivity was 98.97-100% for the detection of known VOC-positive samples, specificity was 97.2-100%, limit of detection was 2-116 copies/reaction, intra- and interassay variability was less than 5%, and no cross-reactivity with common respiratory pathogens was observed with any assay. A subset of rRT-PCR- positive VOC samples were further characterized by genome sequencing. A comparison of the lineage designation by the VOC rRT-PCR assays and genome sequencing for the detection of the Alpha, Beta, Gamma, Delta and Omicron variants showed clinical sensitivities of 99.97-100 %, clinical specificities of 99.6-100 %, positive predictive values of 99.8-100%, and negative predictive values of 99.98-100 %. We have implemented these rRT-PCR assays targeting discriminatory single nucleotide polymorphisms for ongoing VOC screening of SARS-CoV-2 positive samples for surveillance purposes. This has proven extremely useful in providing close to real-time molecular surveillance to monitor the emergence of Alpha, the replacement of Alpha by Delta, and the replacement of Delta by Omicron. While the design, validation and implementation of the variant specific PCR targets is an ever-evolving approach, we find the turn-around-time, high throughput and sensitivity to be a useful complementary approach for SARS-CoV-2 genome sequencing for surveillance purposes in the province of Alberta, Canada.

Indexed as

COVID-19Real-Time Polymerase Chain ReactionSARS-CoV-2HumansMutationRNA, ViralSensitivity and SpecificityRNA, ViralCOVID-19Real-time RT-PCRSARS-CoV-2Variants of concern

Identifiers

PMID35644262
PMCPMC9134755
OpenAlexW4281558536

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.